Literature DB >> 1453586

Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood.

M M Fitzpatrick1, V Shah, R S Trompeter, M J Dillon, T M Barratt.   

Abstract

Polymorphoneutrophil leucocytes (PMNLs) are implicated in the pathogenesis of diarrhea-associated hemolytic uremic syndrome (D+ HUS). We investigated mechanisms of PMNL involvement by measuring tumor necrosis factor alpha (TNF alpha) and the novel cytokine, interleukin-8 (IL-8), a potent activator of neutrophils, together with alpha 1- antitrypsin-complexed elastase (alpha 1-AT-E) as a marker of neutrophil degranulation, and anti-neutrophil cytoplasmic antibodies (ANCA). IL-8 was not detected in the 17 normal children, but was significantly elevated in 20 of 25 D+ HUS children (P less than 0.005), and in three of nine children with non-diarrhea-associated (D-) HUS. Sequential data showed that IL-8 peaked transiently in the circulation, reaching a maximum just before a more protracted burst of alpha 1-AT-E. The IL-8 levels correlated significantly with circulating alpha 1-AT-E concentrations (r = 0.50, P less than 0.05). In D+ HUS IL-8 levels also correlated with the PMNL count (r = 0.63, P less than 0.005), and the highest values were seen in those children who died in the acute phase of the disease. TNF alpha was raised in only 1 of 16 D+ HUS children and in no patients were ANCA detected. The data suggest that PMNLs in HUS are recruited by IL-8, that this cytokine plays a key role in the PMNL activation which occurs, and that agents which suppress this recruitment and activation might play a therapeutic role in this disorder.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1453586     DOI: 10.1038/ki.1992.372

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  37 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Molecular damage and induction of proinflammatory cytokines in human endothelial cells exposed to Shiga toxin 1, Shiga toxin 2, and alpha-sarcin.

Authors:  Maurizio Brigotti; Domenica Carnicelli; Elisa Ravanelli; Antonio González Vara; Chiara Martinelli; Roberta R Alfieri; Pier Giorgio Petronini; Piero Sestili
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

3.  Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides.

Authors:  Lisa M Harrison; Christel van den Hoogen; Wilhelmina C E van Haaften; Vernon L Tesh
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation.

Authors:  James K Roche; Tiffany R Keepers; Lisa K Gross; Regina M Seaner; Tom G Obrig
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

5.  Activation of the Akt-NF-kappaB pathway by subtilase cytotoxin through the ATF6 branch of the unfolded protein response.

Authors:  Hiroaki Yamazaki; Nobuhiko Hiramatsu; Kunihiro Hayakawa; Yasuhiro Tagawa; Maro Okamura; Ryouji Ogata; Tao Huang; Shotaro Nakajima; Jian Yao; Adrienne W Paton; James C Paton; Masanori Kitamura
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

Review 6.  Antineutrophil cytoplasm antibodies and vasculitis.

Authors:  M C Nash; M J Dillon
Journal:  Arch Dis Child       Date:  1997-09       Impact factor: 3.791

Review 7.  Advances in haemolytic uraemic syndrome.

Authors:  C M Taylor; L A Monnens
Journal:  Arch Dis Child       Date:  1998-02       Impact factor: 3.791

8.  Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli infection.

Authors:  C D Inward; M Varagunam; D Adu; D V Milford; C M Taylor
Journal:  Arch Dis Child       Date:  1997-08       Impact factor: 3.791

Review 9.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

10.  Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS.

Authors:  D Maroeska Te Loo; Nienke Bosma; Victor Van Hinsbergh; Paul Span; Rob De Waal; Ruud Clarijs; C Sweep; Leo Monnens; Lambertus Van Den Heuvel
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.